In some prospective studies published to date on the analysis of BRAF V600E mutation in patients with papillary thyroid carcinoma, the determination of the mutation was largely undertaken at the time of the total thyroidectomy surgical act or with the surgical reintervention for tumor relapse [12,13]. Here, BRAF is linked to neoplasm.